Knee supplement pilot missed its main endpoint despite some reported improvements
In people with mild to moderate knee pain, a supplement trial reported some advantages over placebo but missed its primary endpoint. Pain improved in both groups.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The supplement group reported improvements in some knee symptoms, sport and recreation, and quality-of-life measures compared with placebo. However, the trial did not meet its primary endpoint, which the abstract does not identify. Pain improved in both groups, so those pain results do not establish an advantage for the supplement over placebo.
This was a pilot study, and its primary endpoint was not achieved or identified in the abstract. Reported percentage changes lack sufficient detail to distinguish changes within groups from the size of differences between groups.
Reported gains were selective
The knee questionnaire covered symptoms and daily life. Selected areas favored the supplement group, while chair-stand performance improved in both groups. Other physical performance measures showed no statistically significant differences, leaving the overall pattern mixed.
Biomarker results remained uncertain
Mental health scores were unchanged, while the measured biomarkers showed no statistically significant changes. The authors described safety favorably, but the abstract gives no adverse-event counts, limiting what readers can assess about harms.
The original publication
Effects of cartilage-supporting nutritional supplementation on knee osteoarthritis symptoms and quality of life in a 12-week randomized double-blind placebo-controlled pilot study.
Fladerer-Grollitsch JP, Klein T, Kompek A et al.
Sci Rep · 2025
- PubMed ID
- 40664872
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.